Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Cheryl Blanchard, a member of Anika Therapeutics’ board of directors, has assumed the role of the interim CEO following the death of the company’s CEO Joseph Darling. Anika is currently in the process of looking for a new CEO.
Aprea Therapeutics has appointed Gregory Wessels to a newly created position of vice president of commercial. Prior, Wessels served as executive director of U.S. marketing for lymphoma and acute myeloid leukemia at Bristol-Myers Squibb.
AskBio has appointed Anna Tretiakova as the firm’s new senior vice president of product development. Tretiakova’s most recent focus was in gene therapy at Swan Therapeutics.
Blaise Coleman will succeed Paul Campanelli as president and CEO at Endo International. Coleman has served as Endo’s executive vice president and chief financial officer since 2016.
Enterprise Therapeutics has named David Morris as the company’s new chief medical officer. Morris was most recently managing director at the Novartis Venture Fund, where he will remain as an operating partner.
Everest Medicines has found its new CEO in Eli Lilly veteran Kerry Blanchard. Prior to this appointment, Blanchard was senior vice president of China drug development at Eli Lilly.
Evolution Health Group
Evolution Health Group has named Michael Stevinson executive vice president of the communications firm’s blulava division. Most recently, Stevinson was executive principal and managing director at ICON.
Australia-based George Clinical named James Cheong as its new CEO. Cheong was most recently head of clinical operations of the Chinese market for Boehringer Ingelheim.
Michael Quigley is now senior vice president of research biology at Gilead Sciences. Prior to joining Gilead, Quigley served as Bristol-Myers Squibb’s vice president and head of the tumor microenvironment modulation thematic research center and site head of the Redwood City, Calif., location.
Fuxing Tang has been appointed to the role of chief technology officer and vice president of formulation R&D and product development at Hua Medicine, joining the company after most recently serving as director of pharmaceutical sciences at Teva Pharmaceuticals.
Loretta Itri has joined Immunomedics as its new chief medical officer. Previously, Itri oversaw global health sciences and medical affairs at The Medicines Company.
Antonio Gualberto, founder and chief medical officer of early-stage biotech Kura Oncology, has been tapped as Eisai’s H3 Biomedicine’s chief medical officer.
Lyndra Therapeutics has named Richard Scanton the company’s new chief medical officer. Prior to this appointment, Scranton was chief medical officer at Pacira Pharmaceuticals.
Rentschler Biopharma has tapped Grace Kim as the company’s vice president of business development - North America and APAC, a newly created position within the organization. Recently, Kim was vice president at Northway Biotechpharma.
Robert Carroll has been appointed to the roles of partner and head of investor relations at Sofinnova Partners. Prior to this appointment, Carroll co-led PwC’s global fundraising advisory platform.
Philippe Menu has been named chief medical officer of Sophia Genetics, joining the company after most recently serving as a leader in the McKinsey Cancer Center.